Insmed to Host Third Quarter 2018 Financial Results Conference Call on Tuesday, October 30, 2018
23 Octobre 2018 - 2:30PM
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical
company focused on the unmet needs of patients with rare diseases,
today announced that it will release its third quarter 2018
financial results on Tuesday, October 30, 2018.
Insmed management will host a conference call for investors
beginning at 8:30 a.m. ET on Tuesday, October 30, 2018 to discuss
the financial results and provide a business update.
Shareholders and other interested parties may participate in the
conference call by dialing (844) 707-0669 (domestic) or (703)
639-1223 (international) and referencing conference ID number
2556408. The call will also be webcast live on the company's
website at www.insmed.com.
A replay of the conference call will be accessible approximately
two hours after its completion through November 6, 2018 by dialing
(855) 859-2056 (domestic) or (404) 537-3406 (international) and
referencing conference ID number 2556408. A webcast of the call
will also be archived for 90 days under the Investor Relations
section of the company's website at www.insmed.com.
About Insmed
Insmed Incorporated is a global biopharmaceutical company on a
mission to transform the lives of patients with serious and rare
diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin
liposome inhalation suspension), which is approved in the United
States for the treatment of Mycobacterium avium complex (MAC) lung
disease as part of a combination antibacterial drug regimen for
adult patients with limited or no alternative treatment options.
MAC lung disease is a rare and often chronic infection that can
cause irreversible lung damage and can be fatal. Insmed's
earlier-stage clinical pipeline includes INS1007, a novel oral
reversible inhibitor of dipeptidyl peptidase 1 with therapeutic
potential in non-cystic fibrosis bronchiectasis and other
inflammatory diseases, and INS1009, an inhaled formulation of a
treprostinil prodrug that may offer a differentiated product
profile for rare pulmonary disorders, including pulmonary arterial
hypertension. For more information, visit www.insmed.com.
Contact:Blaine Davis Insmed Incorporated (908) 947-2841
blaine.davis@insmed.com
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024